Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS)

Inclusion Criteria: * Age ≥ 18 years at the day of consenting to the study * Patient with histologically confirmed locally advanced (unresectable) pancreatic adenocarcinoma according to the National Comprehensive Cancer Network (NCCN) 2020 classification * Unifocal pancreatic lesion with a maximum diameter of 4 cm * Non-progressive disease after 4 months of first-line chemotherapy or after 2 months of chemotherapy in case of limiting toxicity contraindicating continuation of chemotherapy; * Preoperative imaging including CT-scan, MRI of the liver and Positron Emission Computed Tomography scan (PET-CT scan) (except for absolute medical contraindications), within 4 weeks prior to HIFU treatment * Eastern Cooperative Oncology Group performance status ≤ 2 * Adequate hematologic parameters defined by platelets ≥ 100 Giga/l and hemoglobin ≥ 8 g/dl * Ability to understand and willingness for follow-up visits * Patient affiliated to a health insurance scheme (or beneficiary of such a scheme) * Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment Exclusion Criteria: * Local recurrence of previously operated pancreatic cancer * Metastatic pancreatic carcinoma * History of major pancreatic resection * Chemotherapy completed less than 2 weeks ago * History of radiotherapy to the pancreas * Pregnant women * Possibility of R0 resection with venous reconstruction * Inability to undergo study follow-up for …